Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek investigation

This article was originally published in The Tan Sheet

Executive Summary

Kentucky state, local fire officials "are considering whether hexane discharges from our operations were a factor" in a March 12 explosion at a public wastewater treatment works in Winchester, according to firm's March 17 110-Q filing. "State fire marshal issued a finding that Martek had not met certain applicable requirements and directed us to prevent any introduction of hexane into the sanitary sewer system," the filing states, noting "we had already done so." Firm says it is cooperating with investigation and "still gathering information about the incident," but does "not believe this matter will have a material impact on production output or our results of operations." Nutritional oils manufacturer recently began using a new building at its Winchester plant for shipping, packaging, cold storage and administration...

You may also be interested in...



Martek Production Capacity Expected To Reach $200 Mil.-$250 Mil. in 2004

Martek plans to spend between $20 mil. and $30 mil. over the next 12 months on increasing its fermentation capacity, the Columbia, Md.-based firm said during a June 3 analysts call

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel